Dr. Neelapu on Potential Advantages of Allogeneic CAR T-Cell Therapy in Lymphoma
Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.
Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.
Findings from the first-in-human phase 1 ALPHA study showed a manageable safety profile with the investigational anti-CD19 allogeneic CAR T-cell therapy ALLO-501 in combination with the anti-CD52 monoclonal antibody ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.
Longer follow-up is needed to assess whether allogeneic CAR T-cell therapy elicits similar efficacy and durability as autologous CAR T-cell therapy, says Neelapu. However, allogeneic CAR T-cell therapy may offer potential advantages over autologous CAR T-cell therapy.
These potential advantages include reduced manufacturing cost, increased accessibility for patients, and lower treatment cost for patients, concludes Neelapu.
